DNMT3A del TET2 del
|
acute myeloid leukemia
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lynparza (olaparib) inhibited colony formation of mouse acute myeloid leukemia cells harboring TET2 and DNMT3A deletion along with a FLT3-ITD mutation in culture (PMID: 34215619).
|
34215619
|
TET2 mutant
|
acute myeloid leukemia
|
sensitive
|
Olaparib
|
Preclinical - Patient cell culture |
Actionable |
In a preclinical study, Lynparza (olaparib) treatment inhibited colony formation in patient-derived acute myeloid leukemia cells harboring a TET2 mutation along with FLT3-ITD and NPM1 mutation in culture (PMID: 34215619).
|
34215619
|
FLT3 exon 14 ins TET2 loss
|
acute myeloid leukemia
|
sensitive
|
Quizartinib + Talazoparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of Vanflyta (quizartinib) and Talzenna (talazoparib) decreased colony formation in mouse acute myeloid leukemia cells harboring a FLT3-ITD mutation and TET2 loss in culture (PMID: 34215619).
|
34215619
|
FLT3 exon 14 ins TET2 loss
|
acute myeloid leukemia
|
sensitive
|
Doxorubicin + Olaparib + Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of Lynparza (olaparib), Adriamycin (doxorubicin), and Vanflyta (quizartinib) increased DNA double-strand breaks and decreased colony formation in mouse acute myeloid leukemia cells harboring a FLT3-ITD mutation and TET2 loss in culture (PMID: 34215619).
|
34215619
|
DNMT3A mut FLT3 exon 14 ins TET2 mut
|
acute myeloid leukemia
|
sensitive
|
Doxorubicin + Olaparib + Quizartinib
|
Preclinical - Patient cell culture |
Actionable |
In a preclinical study, the combination of Lynparza (olaparib), Adriamycin (doxorubicin), and Vanflyta (quizartinib) inhibited colony formation in patient-derived acute myeloid leukemia cells harboring FLT3-ITD and DNMT3A and TET2 mutations along with an NPM1 mutation in culture (PMID: 34215619).
|
34215619
|
DNMT3A loss
|
acute myeloid leukemia
|
resistant
|
Talazoparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, mouse acute myeloid leukmia cells harboring DNMT3A loss along with a FLT3-ITD mutation were resistant to Talzenna (talazoparib) in culture (PMID: 34215619).
|
34215619
|
TET2 del
|
acute myeloid leukemia
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lynparza (olaparib) inhibited colony formation of mouse acute myeloid leukemia cells harboring TET2 deletion along with a FLT3-ITD mutation in culture (PMID: 34215619).
|
34215619
|
DNMT3A loss
|
acute myeloid leukemia
|
resistant
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, mouse acute myeloid leukemia cells harboring DNMT3A loss along with various oncogenic tyrosine kinase mutations were resistant to Lynparza (olaparib) in culture (PMID: 34215619).
|
34215619
|
JAK2 V617F TET2 loss
|
acute myeloid leukemia
|
sensitive
|
Hydroxyurea + Olaparib + Rituximab
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lynparza (olaparib), Droxia (hydroxyurea), and Rituxan (rituximab) combination treatment decreased colony formation in mouse acute myeloid leukemia cells harboring JAK2 V617F and TET2 loss in culture (PMID: 34215619).
|
34215619
|
FLT3 exon 14 ins TET2 mut
|
acute myeloid leukemia
|
sensitive
|
Doxorubicin + Olaparib + Quizartinib
|
Preclinical - Patient cell culture |
Actionable |
In a preclinical study, the combination of Lynparza (olaparib), Adriamycin (doxorubicin), and Vanflyta (quizartinib) inhibited colony formation in patient-derived acute myeloid leukemia cells harboring FLT3-ITD and a TET2 mutation along with an NPM1 mutation in culture (PMID: 34215619).
|
34215619
|
DNMT3A mut TET2 mut
|
acute myeloid leukemia
|
sensitive
|
Olaparib
|
Preclinical - Patient cell culture |
Actionable |
In a preclinical study, Lynparza (olaparib) treatment inhibited colony formation in patient-derived acute myeloid leukemia cells co-harboring a DNMT3A and TET2 mutation along with FLT3-ITD and NPM1 mutation in culture (PMID: 34215619).
|
34215619
|
TET2 loss
|
acute myeloid leukemia
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lynparza (olaparib) inhibited colony formation in mouse acute myeloid leukemia cells harboring TET2 loss along with various oncogenic tyrosine kinase mutations in culture (PMID: 34215619).
|
34215619
|
DNMT3A loss TET2 loss
|
acute myeloid leukemia
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lynparza (olaparib) inhibited colony formation in murine acute myeloid leukemia cells harboring TET2 and DNMT3A loss along wtih various oncogenic tyrosine kinase mutations in culture (PMID: 34215619).
|
34215619
|
FLT3 exon 14 ins TET2 loss
|
acute myeloid leukemia
|
sensitive
|
Olaparib + Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of Lynparza (olaparib) and Vanflyta (quizartinib) decreased colony formation in murine acute myeloid leukemia cells harboring a FLT3-ITD mutation and TET2 loss in culture (PMID: 34215619).
|
34215619
|
TET2 A1505T TET2 mut
|
acute myeloid leukemia
|
sensitive
|
Olaparib
|
Preclinical - Patient cell culture |
Actionable |
In a preclinical study, Lynparza (olaparib) treatment inhibited colony formation of patient-derived acute myeloid leukemia cells harboring FLT3-ITD and a TET2 mutation along with an NPM1 mutation and expressing TET2 A1505T in culture (PMID: 34215619).
|
34215619
|
DNMT3A mutant
|
acute myeloid leukemia
|
resistant
|
Olaparib
|
Preclinical - Patient cell culture |
Actionable |
In a preclinical study, patient-derived acute myeloid leukemia cells harboring a DNMT3A mutation along with FLT3-ITD and NPM1 mutation were resistant to Lynparza (olaparib) in culture (PMID: 34215619).
|
34215619
|
DNMT3A mut FLT3 exon 14 ins TET2 mut
|
acute myeloid leukemia
|
sensitive
|
Olaparib + Quizartinib
|
Preclinical - Patient cell culture |
Actionable |
In a preclinical study, the combination of Lynparza (olaparib) and Vanflyta (quizartinib) inhibited colony formation in patient-derived acute myeloid leukemia cells harboring FLT3-ITD and DNMT3A and TET2 mutations along with an NPM1 mutation in culture (PMID: 34215619).
|
34215619
|
DNMT3A del
|
acute myeloid leukemia
|
resistant
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, mouse acute myeloid leukemia cells harboring a DNMT3A deletion along with FLT3-ITD mutation were resistant to Lynparza (olaparib) in culture (PMID: 34215619).
|
34215619
|
FLT3 exon 14 ins TET2 mut
|
acute myeloid leukemia
|
sensitive
|
Olaparib + Quizartinib
|
Preclinical - Patient cell culture |
Actionable |
In a preclinical study, the combination of Lynparza (olaparib) and Vanflyta (quizartinib) inhibited colony formation in patient-derived acute myeloid leukemia cells harboring FLT3-ITD and a TET2 mutation along with an NPM1 mutation in culture (PMID: 34215619).
|
34215619
|
DNMT3A loss TET2 loss
|
acute myeloid leukemia
|
sensitive
|
Talazoparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Talzenna (talazoparib) decreased colony formation in murine acute myeloid leukemia cells harboring TET2 and DNMT3A loss along with a FLT3-ITD mutation in culture (PMID: 34215619).
|
34215619
|
DNMT3A loss FLT3 exon 14 ins TET2 loss
|
acute myeloid leukemia
|
sensitive
|
Quizartinib + Talazoparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of Vanflyta (quizartinib) and Talzenna (talazoparib) decreased colony formation in mouse acute myeloid leukemia cells harboring a FLT3-ITD mutation and TET2 and DNMT3A loss in culture (PMID: 34215619).
|
34215619
|
JAK2 V617F TET2 loss
|
acute myeloid leukemia
|
sensitive
|
Olaparib + Rituximab
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, treatment with the combination of Lynparza (olaparib) and Rituxan (rituximab) decreased colony formation in mouse acute myeloid leukemia cells harboring JAK2 V617F and TET2 loss in culture (PMID: 34215619).
|
34215619
|
DNMT3A loss FLT3 exon 14 ins TET2 loss
|
acute myeloid leukemia
|
sensitive
|
Olaparib + Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of Lynparza (olaparib) and Vanflyta (quizartinib) decreased colony formation in mouse acute myeloid leukemia cells harboring a FLT3-ITD mutation and TET2 and DNMT3A loss in culture (PMID: 34215619).
|
34215619
|
TET2 loss
|
acute myeloid leukemia
|
sensitive
|
Talazoparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Talzenna (talazoparib) decreased colony formation in mouse acute myeloid leukemia cells harboring TET2 loss along with a FLT3-ITD mutation in culture (PMID: 34215619).
|
34215619
|
DNMT3A loss FLT3 exon 14 ins
|
acute myeloid leukemia
|
no benefit
|
Quizartinib + Talazoparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the addition of Talzenna (talazaparib) did not enhance the sensitivity of mouse acute myeloid leukemia cells harboring a FLT3-ITD mutation and DNMT3A loss to Vanflyta (quizartinib) treatment compared to Vanflyta (quizartinib) alone in culture (PMID: 34215619).
|
34215619
|
DNMT3A loss FLT3 exon 14 ins TET2 loss
|
acute myeloid leukemia
|
sensitive
|
Doxorubicin + Olaparib + Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of Lynparza (olaparib), Adriamycin (doxorubicin), and Vanflyta (quizartinib) increased DNA double-strand breaks and decreased colony formation in mouse acute myeloid leukemia cells harboring a FLT3-ITD mutation and TET2 and DNMT3A loss in culture (PMID: 34215619).
|
34215619
|